AbCellera Biologics (ABCL) Fundamental Analysis: Revenue, Earnings & Valuation

3.52 / 10

Netural

Fundamental assessment rates neutral with a 3.5/10 quality score. PB‑ROE and Revenue‑MV show modest strength, while Asset‑MV and Fixed‑asset turnover lag. Overall, the balance sheet and earnings metrics are sub‑par, recommending prudence.

Analysis Checks(7/10)

Revenue-MV

Value-1.17

Score2/3

Weight19.34%

1M Return8.45%

Total operating revenue (YoY growth rate %)

Value160.56

Score2/3

Weight-1.90%

1M Return-1.06%

Inventory turnover ratio

Value103.94

Score3/3

Weight15.76%

1M Return6.74%

Gross profit margin (%)

Value100.00

Score2/3

Weight3.59%

1M Return1.69%

PB-ROE

Value-0.31

Score2/3

Weight14.92%

1M Return6.97%

Income tax / Total profit (%)

Value17.56

Score1/3

Weight-0.91%

1M Return-0.50%

Fixed assets turnover ratio

Value0.20

Score1/3

Weight-2.20%

1M Return-1.24%

Cost of sales ratio (%)

Value64.41

Score3/3

Weight9.12%

1M Return4.32%

Asset-MV

Value-0.55

Score1/3

Weight28.27%

1M Return11.07%

Cash-MV

Value0.02

Score2/3

Weight14.00%

1M Return5.94%

Is ABCL undervalued or overvalued?

ABCL scores 3.52/10 on fundamentals and holds a Fair valuation at present. Backed by its -14.47% ROE, -194.88% net margin, -6.79 P/E ratio, 1.03 P/B ratio, and 10.91% earnings growth, these metrics solidify its Netural investment rating.